A Phase 1, Open Label, Two Period, Randomized, Cross Over Scintigraphy Study Assessing Nasal Deposition of a Single Dose of a Ciclesonide Radiolabeled Solution Following Nasal Inhalation of a Novel Nasal Metered Dose Inhaler (MDI) and of a Mometasone Furoate Monohydrate Radiolabeled Suspension Via an Aqueous (AQ) Nasal Spray.

Trial Profile

A Phase 1, Open Label, Two Period, Randomized, Cross Over Scintigraphy Study Assessing Nasal Deposition of a Single Dose of a Ciclesonide Radiolabeled Solution Following Nasal Inhalation of a Novel Nasal Metered Dose Inhaler (MDI) and of a Mometasone Furoate Monohydrate Radiolabeled Suspension Via an Aqueous (AQ) Nasal Spray.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2014

At a glance

  • Drugs Ciclesonide (Primary) ; Mometasone
  • Indications Perennial allergic rhinitis; Seasonal allergic rhinitis
  • Focus Pharmacokinetics
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 15 Sep 2011 Actual end date (July 2011) added as reported by ClinicalTrials.gov.
    • 15 Sep 2011 Status changed from recruiting to completed as repored by ClinicalTrials.gov.
    • 21 Jun 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top